glp 1 mash approval FDA Expands Novo Nordisk's Wegovy to the Fatty Liver Disease What you need to know

This finding holds significant importance, noting that phase 3 studies have typically excluded patients with a history of psychiatric disorders, resulting in a lack of reference data for understanding the long-term consequences of GLP-1 RAs use in patients with obesity

But they were built for different goals and different audiences

Always remember to consult with your healthcare provider for professional advice and never solely depend on self-assessment

Chronic Dis

You can turn up potential problems early, and youll get meaningful blood data to share with your doctor

These drugs can also produce side effects that may spur changes in eating habits, which can lead to safety risks or worse health outcomes if not appropriately managed